According to Zhitong Finance App, Peger Biopharmaceutical-B (02565.HK) announced that on December 12, 2025 (after the trading period), the Company entered into a placement agreement with the Joint Placing Agent. According to this, the Company has agreed to place a total of 5.136,000 shares of the placement shares to no less than six undertakers on a best-effort basis at a price of HK$58.41 per share. Such placed shares will be issued by the Company under general authorization in accordance with the terms and conditions of the agreement contained in the placement agreement.

According to Zhitong Finance App, Peger Biopharmaceutical-B (02565.HK) announced that on December 12, 2025 (after the trading period), the Company entered into a placement agreement with the Joint Placing Agent. According to this, the Company has agreed to place a total of 5.136,000 shares of the placement shares to no less than six undertakers on a best-effort basis at a price of HK$58.41 per share. Such placed shares will be issued by the Company under general authorization in accordance with the terms and conditions of the agreement contained in the placement agreement.